These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23946593)

  • 1. Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.
    Matsumura H; Nirei K; Nakamura H; Higuchi T; Arakawa Y; Ogawa M; Tanaka N; Moriyama M
    World J Gastroenterol; 2013 Aug; 19(30):4887-96. PubMed ID: 23946593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SEN virus infection influences the pathological findings in liver but does not affect the incidence of hepatocellular carcinoma in patients with chronic hepatitis C and liver cirrhosis.
    Moriyama M; Mikuni M; Matsumura H; Nakamura H; Oshiro S; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Tanaka N; Arakawa Y
    Liver Int; 2005 Apr; 25(2):226-35. PubMed ID: 15780043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
    Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
    Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
    Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
    Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
    Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
    Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.
    Pinzone MR; Zanghì AM; Rapisarda L; D'Agata V; Benanti F; Spartà D; Nunnari G; Cacopardo B
    Eur Rev Med Pharmacol Sci; 2014 Dec; 18(2 Suppl):11-5. PubMed ID: 25535185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
    Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
    Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients.
    Yen YH; Lin MT; Kuo FY; Chang KC; Tsai MC; Tseng PL; Wu CK; Lin JT; Hu TH; Lu SN; Wang JH; Hung CH; Chen CH
    Liver Int; 2018 Jun; 38(6):1064-1073. PubMed ID: 29164767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
    Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
    Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.
    Osaki Y; Ueda Y; Marusawa H; Nakajima J; Kimura T; Kita R; Nishikawa H; Saito S; Henmi S; Sakamoto A; Eso Y; Chiba T
    J Gastroenterol; 2012 Apr; 47(4):444-51. PubMed ID: 22105231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C without sustained response to combination therapy.
    Chang KC; Ye YH; Wu CK; Lin MT; Tsai MC; Tseng PL; Hu TH
    J Formos Med Assoc; 2018 Nov; 117(11):1011-1018. PubMed ID: 29254684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
    Nagaoki Y; Aikata H; Nakano N; Shinohara F; Nakamura Y; Hatooka M; Morio K; Kan H; Fujino H; Kobayashi T; Fukuhara T; Masaki K; Ono A; Nakahara T; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Imamura M; Takahashi S; Kawakami Y; Ochi H; Chayama K;
    J Gastroenterol Hepatol; 2016 May; 31(5):1009-15. PubMed ID: 26584407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
    Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
    Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
    Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.